First Patient Dosed in Global CSU Study
VCTC Doses First Patient in Global Celldex Trial for Chronic Spontaneous Urticaria
This week marks an exciting milestone for VCTC, as we successfully dosed our first patient in a global clinical trial investigating a promising new treatment for Chronic Spontaneous Urticaria (CSU).
CSU is a distressing and often misunderstood skin condition, characterised by the spontaneous appearance of hives (wheals), swelling (angioedema), and intense itching that can significantly impact quality of life. What sets CSU apart is its unpredictability and persistence - symptoms can last for months or even years, often with no identifiable trigger. For many patients, standard antihistamine therapy provides little or no relief, leaving them searching for alternative options.
The investigational treatment being assessed in this trial is aimed at patients with CSU who remain symptomatic despite current therapies. By targeting the underlying biological mechanisms of the condition, the study hopes to offer a more effective and longer-lasting solution for those affected.
The trial is truly global in scope, aiming to recruit 915 participants across 250 to 300 sites worldwide. At VCTC, enrolled patients will be part of the study for approximately 68 weeks, with monthly clinic visits to receive their assigned treatment, undergo safety monitoring, and complete a series of efficacy assessments.
Our involvement in this trial reflects VCTC’s continued commitment to advancing care for people living with chronic, under-recognised conditions. We’re proud to play a part in this collaborative effort and to contribute high-quality data that could shape the future of CSU treatment.
We would like to thank our clinical team, our dedicated study participants, and our sponsors and collaborators for helping us reach this important 'first patient in' milestone. It’s a privilege to be part of research that has the potential to bring new hope to those who need it most.
If you’d like to learn more about our work or participate in a clinical trial, please get in touch.
